AtonRa Partners Lowers Stake in Insulet Co. (NASDAQ:PODD)

AtonRa Partners decreased its position in shares of Insulet Co. (NASDAQ:PODD) by 7.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,434 shares of the medical instruments supplier’s stock after selling 278 shares during the quarter. Insulet comprises 1.5% of AtonRa Partners’ holdings, making the stock its 12th biggest position. AtonRa Partners’ holdings in Insulet were worth $745,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Wolff Wiese Magana LLC lifted its stake in shares of Insulet by 2,680.0% during the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock worth $30,000 after purchasing an additional 134 shares during the period. Parkside Financial Bank & Trust boosted its stake in Insulet by 251.0% in the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 123 shares during the last quarter. Allworth Financial LP boosted its stake in Insulet by 104.5% in the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 92 shares during the last quarter. Lindbrook Capital LLC increased its stake in shares of Insulet by 64.1% during the 4th quarter. Lindbrook Capital LLC now owns 192 shares of the medical instruments supplier’s stock valued at $42,000 after acquiring an additional 75 shares during the last quarter. Finally, BluePath Capital Management LLC purchased a new position in shares of Insulet during the 3rd quarter worth about $31,000.

Insulet Stock Up 2.4 %

Shares of NASDAQ:PODD traded up $4.07 during mid-day trading on Monday, hitting $170.26. 602,109 shares of the company traded hands, compared to its average volume of 859,181. The firm has a market cap of $11.92 billion, a P/E ratio of 58.51, a PEG ratio of 2.99 and a beta of 0.98. Insulet Co. has a 52-week low of $125.82 and a 52-week high of $335.91. The firm’s 50 day simple moving average is $171.09 and its 200 day simple moving average is $180.25. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. The company had revenue of $509.80 million for the quarter, compared to analyst estimates of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. The business’s quarterly revenue was up 37.9% on a year-over-year basis. During the same quarter last year, the firm posted $0.55 earnings per share. On average, equities analysts anticipate that Insulet Co. will post 3.08 EPS for the current year.

Insiders Place Their Bets

In related news, Director Shacey Petrovic sold 11,609 shares of the business’s stock in a transaction dated Wednesday, February 28th. The stock was sold at an average price of $162.92, for a total value of $1,891,338.28. Following the transaction, the director now owns 2,567 shares in the company, valued at $418,215.64. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 0.47% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the stock. Stifel Nicolaus boosted their target price on shares of Insulet from $163.00 to $208.00 and gave the company a “hold” rating in a report on Monday, February 5th. Barclays lowered their price objective on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a research note on Monday, February 26th. JPMorgan Chase & Co. increased their target price on Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a research report on Friday, February 23rd. Finally, Piper Sandler lowered their price target on Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and a consensus target price of $243.21.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.